General FAQ

When was Ginkgo founded?

Ginkgo was founded in 2008 by Barry Canton, Austin Che, Jason Kelly, Tom Knight, and Reshma Shetty. Tom, a computer science professor at MIT who had been part of the early days of the computer revolution, saw another revolution on the horizon: what could be possible if we could program cells as easily as we program computers? Austin, Barry, Jason, and Reshma, graduate students at MIT at the time, were inspired by Tom’s vision and the prospect of synthetic biology.

back to top

What is Ginkgo’s mission?

Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people and our culture is grounded in whether or not it will advance our mission.

back to top

Where are Ginkgo's corporate headquarters?

We are headquartered at 27 Drydock, Boston, MA 02210.

back to top

Who is on Ginkgo’s Management Team?

Information on our management team can be found here.

back to top

Who is on Ginkgo’s Board of Directors?

Information on our Board of Directors can be found here.

back to top

What is Ginkgo’s ticker symbol? What exchange does Ginkgo trade on?

Our Class A common stock and our warrants trade under the ticker symbols “DNA” and “DNA.WS”, respectively, on the New York Stock Exchange.

back to top

When did Ginkgo go public?

We began trading on the New York Stock Exchange on September 17, 2021.

back to top

Where can I find information on ESG and corporate governance?

Information on ESG and corporate governance can be found here.

back to top

Where can I find the latest Ginkgo company news and press releases?

The latest company news and press releases can be found here.

back to top

Where can I find information on Ginkgo’s filing with the Securities and Exchange Commission (SEC)?

Ginkgo’s SEC filings can be found here.

back to top

Who is Ginkgo’s transfer agent?

Our transfer agent is Computershare Trust Company, N.A.

back to top

Who should I contact for investor and press related inquiries?

For investor related inquiries, please contact investors@ginkgobioworks.com. For press related inquiries, please contact press@ginkgobioworks.com.

back to top

Which sell-side research analysts cover Ginkgo?

Ginkgo began trading on the NYSE on September 17th, 2021. To date, Harsh Pappu from HSBC, Matt Larew and Bhavan Suri from William Blair, and Rahul Sarugaser from Raymond James have initiated coverage on Ginkgo. We will continue to update our IR website, as additional analysts begin to initiate coverage.

back to top

About Ginkgo

What is synthetic biology?

Synthetic biology is the idea that we can program cells (biological machines) in the same way that we program computers. Biology runs on digital code (like a computer’s 0s and 1s) in the form of DNA, made up of A’s, T’s, C’s, and G’s, and we can read and write it to program cells. This allows synthetic biologists to reimagine the possibilities of living things, from bacteria that fight cancer to rewilding whole ecosystems. The billions-year-old tools of cells—enzymes that cut, copy, and paste sequences of DNA code—are being leveraged by humans to read, write, and edit DNA in the lab. For more information and inspiration, please visit syntheticbiology.com.

back to top

What does Ginkgo do?

Ginkgo is building the industry-standard horizontal platform for cell programming. Customers come to Ginkgo with a product specification in mind - perhaps they want to discover a new therapeutic or create a way to produce a molecule with biology rather than traditional methods like physical extraction. We use our platform to program cells on behalf of our customers to meet their product specification. These “cell programs” are designed to enable biological production of products as diverse as novel therapeutics, key food ingredients, and chemicals currently derived from petroleum.

Our platform is used to design, write, and debug DNA code in engineered organisms to execute programs for our customers. Our Foundry leverages proprietary software, automation, and data analytics to reduce the cost of cell programming. Our Codebase consists of reusable biological assets that helps accelerate the engineering process.

back to top

What is Ginkgo’s platform?

The foundation of our platform includes two core assets that execute a wide variety of cell programs for customers according to their specifications: our Foundry and our Codebase.

Our Foundry wraps proprietary software and automation around core cell engineering workflows—designing DNA, writing DNA, inserting that DNA into cells, testing to measure cell performance—and leverages data analytics and data science to inform each iteration of design.

Our Codebase includes both our physical (engineered cells and genetic parts) and digital (genetic sequences and performance data) biological assets, and accumulates as we execute more cell programs on the platform. Every program, whether successful or not, generates valuable Codebase and helps inform future experimental designs and provides reusable genetic parts, making our cell program designs more efficient.


back to top

How does Ginkgo get compensated?

The key input into our unit economics is a cell program. For each of these cell programs, we generate economic value in two primary ways. First, we charge usage-based fees for work done in the Foundry, similar to how one might pay a cloud computing platform based on the amount of compute required to run a SaaS application. Second, we share in the downstream value of the programs that are completed on our platform. This value share can be recognized in a variety of manners including royalties , equity, or lump-sum commercial milestone payments.

back to top